Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paul Mischel

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentPathology
    Address9500 Gilman Drive #0753
    CA La Jolla 92093
    Phone858-534-6080
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      The role of mTORC2 in reprogramming cancer cell metabolism
      NIH/NINDS R01NS073831Jun 15, 2011 - May 31, 2021
      Role: Principal Investigator
      Glioblastoma - Molecular Analysis for Clinical Trials
      NIH/NINDS R01NS050151Dec 1, 2004 - Nov 30, 2009
      Role: Principal Investigator
      Trk receptor mediated apoptosis of medulloblastoma cells
      NIH/NINDS K08NS043147Sep 20, 2001 - Aug 31, 2006
      Role: Principal Investigator
      TEMPORALLY DEPENDENT MECHANISMS OF NEUROTROPHIN 3 ACTION
      NIH/NINDS F32NS010301Jul 1, 1997
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Liu F, Mischel P. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. Wiley Interdiscip Rev Syst Biol Med. 2017 Sep 11. PMID: 28892308.
        View in: PubMed
      2. Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel P, Cavenee WK, Furnari FB. Glioblastoma cellular cross-talk converges on NF-?B to attenuate EGFR inhibitor sensitivity. Genes Dev. 2017 Jul 19. PMID: 28724615.
        View in: PubMed
      3. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel P. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017 Feb 08. PMID: 28178237.
        View in: PubMed
      4. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel P. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Oct 13. PMID: 27746144.
        View in: PubMed
      5. Masui K, Shibata N, Cavenee WK, Mischel P. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays. 2016 Sep; 38(9):839-44. PMID: 27427440.
        View in: PubMed
      6. Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel P, Friend S, Ideker T. Challenges in identifying cancer genes by analysis of exome sequencing data. Nat Commun. 2016; 7:12096. PMID: 27417679.
        View in: PubMed
      7. Masui K, Cavenee WK, Mischel P. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol. 2016 Jul; 33(3):161-8. PMID: 27295313.
        View in: PubMed
      8. Villa GR, Mischel P. Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma. Nat Neurosci. 2016 May 26; 19(6):765-7. PMID: 27227363.
        View in: PubMed
      9. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel P, Heath JR, Gini B. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 2016 Apr 11; 29(4):563-73. PMID: 27070703.
        View in: PubMed
      10. Masui K, Mischel P, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016; 134:97-120. PMID: 26948350.
        View in: PubMed
      11. Heath JR, Ribas A, Mischel P. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov. 2016 Mar; 15(3):204-16. PMID: 26669673.
        View in: PubMed
      12. Chang E, Pohling C, Natarajan A, Witney TH, Kaur J, Xu L, Gowrishankar G, L D'Souza A, Murty S, Schick S, Chen L, Wu N, Khaw P, Mischel P, Abbasi T, Usmani S, Mallick P, Gambhir SS. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. J Neurooncol. 2016 Jan; 126(2):253-64. PMID: 26650066.
        View in: PubMed
      13. Masui K, Cavenee WK, Mischel P. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathol. 2015 Nov; 25(6):755-9. PMID: 26526943.
        View in: PubMed
      14. Venneti S, Mischel P. Metabolic Reprogramming in Brain Cancer: A Coordinated Effort. Brain Pathol. 2015 Nov; 25(6):753-4. PMID: 26526942.
        View in: PubMed
      15. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel P. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell. 2015 Oct 15; 60(2):307-18. PMID: 26455392.
        View in: PubMed
      16. Villa GR, Mischel P. Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource. EBioMedicine. 2015 Oct; 2(10):1274-5. PMID: 26629504.
        View in: PubMed
      17. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel P, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1; 121(19):3481-90. PMID: 26177599.
        View in: PubMed
      18. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel P. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A. 2015 Jul 28; 112(30):9406-11. PMID: 26170313.
        View in: PubMed
      19. Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel P, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma. Mol Cancer. 2015; 14(1):127. PMID: 26134617.
        View in: PubMed
      20. Furnari FB, Cloughesy TF, Cavenee WK, Mischel P. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May; 15(5):302-10. PMID: 25855404.
        View in: PubMed
      21. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel P, Kohmura E. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 2015 Apr 1; 125(4):1591-602. PMID: 25798620.
        View in: PubMed
      22. Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel P, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27; 112(4):1107-12. PMID: 25583476.
        View in: PubMed
      23. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel P. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014 Dec; 11(4):255-63. PMID: 25610711.
        View in: PubMed
      24. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel P, Gonias SL, Cavenee WK, Furnari FB. A Urokinase Receptor-Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Res. 2015 Jan 15; 75(2):394-404. PMID: 25432173.
        View in: PubMed
      25. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel P, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A. Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. Clin Cancer Res. 2014 Nov 15; 20(22):5808-22. PMID: 25224277.
        View in: PubMed
      26. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel P, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194.
        View in: PubMed
      27. Bernhart E, Damm S, Heffeter P, Wintersperger A, Asslaber M, Frank S, Hammer A, Strohmaier H, DeVaney T, Mrfka M, Eder H, Windpassinger C, Ireson CR, Mischel P, Berger W, Sattler W. Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro Oncol. 2014 Jul; 16(7):933-45. PMID: 24463355.
        View in: PubMed
      28. Masui K, Cavenee WK, Mischel P. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 2014 Jul; 25(7):364-73. PMID: 24856037.
        View in: PubMed
      29. Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel P, Gordon LK, Wadehra M. Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma. J Biol Chem. 2014 May 16; 289(20):13974-85. PMID: 24644285.
        View in: PubMed
      30. Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer. 2014; 14(1):152. PMID: 24593279.
        View in: PubMed
      31. Masui K, Cavenee WK, Mischel P. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle. 2014 Apr 1; 13(7):1053-4. PMID: 24583874.
        View in: PubMed
      32. Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer. Curr Pharm Des. 2014; 20(15):2619-26. PMID: 23859617.
        View in: PubMed
      33. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel P. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 3; 343(6166):72-6. PMID: 24310612.
        View in: PubMed
      34. Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel P, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 2013; 8(11):e80397. PMID: 24260384.
        View in: PubMed
      35. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel P. mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc. Cell Metab. 2013 Nov 5; 18(5):726-39. PMID: 24140020.
        View in: PubMed
      36. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel P. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15; 19(20):5722-32. PMID: 24030701.
        View in: PubMed
      37. Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. J Nucl Med. 2013 Oct; 54(10):1820-4. PMID: 23978446.
        View in: PubMed
      38. Cloughesy TF, Cavenee WK, Mischel P. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014 Jan 24; 9:1-25. PMID: 23937436.
        View in: PubMed
      39. Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee WK, Cloughesy TF, Christofk HR, Black DL, Mischel P. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013 Jun 4; 17(6):1000-8. PMID: 23707073.
        View in: PubMed
      40. Iwanami A, Cloughesy TF, Cavenee WK, Mischel P. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle. 2013 May 15; 12(10):1473-4. PMID: 23624839.
        View in: PubMed
      41. Langfelder P, Mischel P, Horvath S. When is hub gene selection better than standard meta-analysis? PLoS One. 2013; 8(4):e61505. PMID: 23613865.
        View in: PubMed
      42. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel P. De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. PMID: 23533263.
        View in: PubMed
      43. Eibinger G, Fauler G, Bernhart E, Frank S, Hammer A, Wintersperger A, Eder H, Heinemann A, Mischel P, Malle E, Sattler W. On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. Exp Cell Res. 2013 Jul 15; 319(12):1828-38. PMID: 23541792.
        View in: PubMed
      44. Wei W, Shi Q, Remacle F, Qin L, Shackelford DB, Shin YS, Mischel P, Levine RD, Heath JR. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proc Natl Acad Sci U S A. 2013 Apr 9; 110(15):E1352-60. PMID: 23530221.
        View in: PubMed
      45. Masui K, Gini B, Wykosky J, Zanca C, Mischel P, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 2013 Apr; 34(4):725-38. PMID: 23455378.
        View in: PubMed
      46. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel P. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4339-44. PMID: 23440206.
        View in: PubMed
      47. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, Jung ME, Torres JZ, Liau LM, Christofk HR, Prins RM, Mischel P, Reue K, Graeber TG, Bensinger SJ. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013 May 1; 73(9):2850-62. PMID: 23440422.
        View in: PubMed
      48. Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan S, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly I, Liau L, Cloughesy TC, Mischel P, Mellinghoff IK, Chan TA. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013 Mar; 45(3):253-61. PMID: 23354438.
        View in: PubMed
      49. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel P, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013 Feb 11; 23(2):143-58. PMID: 23352126.
        View in: PubMed
      50. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel P, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013 Mar; 15(3):370-81. PMID: 23328811.
        View in: PubMed
      51. Babic I, Mischel P. Multiple functions of a glioblastoma fusion oncogene. J Clin Invest. 2013 Feb 1; 123(2):548-51. PMID: 23298839.
        View in: PubMed
      52. Lugassy C, Wadehra M, Li X, Corselli M, Akhavan D, Binder SW, Péault B, Cochran AJ, Mischel P, Kleinman HK, Barnhill RL. Pilot study on "pericytic mimicry" and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenviron. 2013 Apr; 6(1):19-29. PMID: 23275074.
        View in: PubMed
      53. Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5):1206-11. PMID: 23182702.
        View in: PubMed
      54. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel P, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013 Mar; 34(3):533-40. PMID: 22997168.
        View in: PubMed
      55. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel P, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 3; 104(19):1458-69. PMID: 22945948.
        View in: PubMed
      56. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel P, Cavenee WK, Furnari FB. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14164-9. PMID: 22891331.
        View in: PubMed
      57. Babic I, Mischel P. Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. Cancer Discov. 2012 Aug; 2(8):676-8. PMID: 22886662.
        View in: PubMed
      58. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel P, Graeber TG. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012; 8:589. PMID: 22735335.
        View in: PubMed
      59. Mischel P. HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metab. 2012 Jun 6; 15(6):789-90. PMID: 22682216.
        View in: PubMed
      60. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel P, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61. PMID: 22670012.
        View in: PubMed
      61. Masui K, Cloughesy TF, Mischel P. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol. 2012 Jun; 38(3):271-91. PMID: 22098029.
        View in: PubMed
      62. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel P, Thomas G, Kozma SC. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012 Jun 20; 4(139):139ra84. PMID: 22539746.
        View in: PubMed
      63. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel P, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. PMID: 22588883.
        View in: PubMed
      64. Muto J, Imai T, Ogawa D, Nishimoto Y, Okada Y, Mabuchi Y, Kawase T, Iwanami A, Mischel P, Saya H, Yoshida K, Matsuzaki Y, Okano H. RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. PLoS One. 2012; 7(3):e33431. PMID: 22428049.
        View in: PubMed
      65. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18. PMID: 22392572.
        View in: PubMed
      66. Tran LM, Chang CJ, Plaisier S, Wu S, Dang J, Mischel P, Liao JC, Graeber TG, Wu H. Determining PTEN functional status by network component deduced transcription factor activities. PLoS One. 2012; 7(2):e31053. PMID: 22347425.
        View in: PubMed
      67. Qi Q, He K, Yoo MH, Chan CB, Liu X, Zhang Z, Olson JJ, Xiao G, Wang L, Mao H, Fu H, Tao H, Ramalingam SS, Sun SY, Mischel P, Ye K. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. J Biol Chem. 2012 Feb 24; 287(9):6113-27. PMID: 22215664.
        View in: PubMed
      68. Mellinghoff IK, Schultz N, Mischel P, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol. 2012; 355:135-69. PMID: 22015553.
        View in: PubMed
      69. Shi Q, Qin L, Wei W, Geng F, Fan R, Shin YS, Guo D, Hood L, Mischel P, Heath JR. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):419-24. PMID: 22203961.
        View in: PubMed
      70. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel P, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMID: 22194965.
        View in: PubMed
      71. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel P, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 2012 Jan 3; 122(1):253-66. PMID: 22156195.
        View in: PubMed
      72. Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res. 2012 Jan; 10(1):156-66. PMID: 22086906.
        View in: PubMed
      73. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel P, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 1; 29(34):4482-90. PMID: 22025148.
        View in: PubMed
      74. Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel P, Cloughesy TF, Kornblum HI, Nelson SF, Liau LM, Tso CL. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res. 2011 Dec; 9(12):1668-85. PMID: 22013079.
        View in: PubMed
      75. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel P. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. PMID: 22059152.
        View in: PubMed
      76. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel P, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011 Sep 20; 108(38):16062-7. PMID: 21900605.
        View in: PubMed
      77. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel P, Fernandez S, Kornblum HI, Nakano I. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One. 2011; 6(9):e24217. PMID: 21915300.
        View in: PubMed
      78. Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel P, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci. 2011 Sep 1; 124(Pt 17):2938-50. PMID: 21878501.
        View in: PubMed
      79. Ellingson BM, Cloughesy TF, Lai A, Mischel P, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Oct; 13(10):1151-61. PMID: 21856685.
        View in: PubMed
      80. Mischel P. Lost - and found - in translation. J Clin Invest. 2011 Aug; 121(8):3357-9. PMID: 21804196.
        View in: PubMed
      81. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel P, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012 Jan; 106(1):111-9. PMID: 21706273.
        View in: PubMed
      82. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel P, Comin-Anduix B, Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011; 9:76. PMID: 21609436.
        View in: PubMed
      83. Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel P, Viapiano M, Kornblum HI. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro Oncol. 2011 Jun; 13(6):622-34. PMID: 21558073.
        View in: PubMed
      84. Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel P, Hawkins C, Guha A. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med. 2011 Apr 11; 208(4):689-702. PMID: 21464220.
        View in: PubMed
      85. Kawahara H, Okada Y, Imai T, Iwanami A, Mischel P, Okano H. Musashi1 cooperates in abnormal cell lineage protein 28 (Lin28)-mediated let-7 family microRNA biogenesis in early neural differentiation. J Biol Chem. 2011 May 6; 286(18):16121-30. PMID: 21378162.
        View in: PubMed
      86. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel P, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Apr; 13(4):401-9. PMID: 21324937.
        View in: PubMed
      87. Cloughesy TF, Mischel P. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res. 2011 Jan 1; 17(1):6-11. PMID: 21208902.
        View in: PubMed
      88. Nathanson D, Mischel P. Charting the course across the blood-brain barrier. J Clin Invest. 2011 Jan; 121(1):31-3. PMID: 21183784.
        View in: PubMed
      89. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel P, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011 Jan 10; 29(2):142-8. PMID: 21135282.
        View in: PubMed
      90. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel P, Moore TB, Kornblum HI. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer. 2010 Oct; 55(4):644-51. PMID: 20589659.
        View in: PubMed
      91. Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, Liu M, Zhang N, Wang S, Angenieux B, Panosyan E, Samuels ER, Park J, Williams D, Konkankit V, Nathanson D, van Dam RM, Phelps ME, Wu H, Liau LM, Mischel P, Lazareff JA, Kornblum HI, Yong WH, Graeber TG, Tseng HR. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res. 2010 Aug 1; 70(15):6128-38. PMID: 20631065.
        View in: PubMed
      92. Wagle N, Nghiemphu L, Lai A, Pope W, Mischel P, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med. 2010; 3:79-85. PMID: 23226044.
        View in: PubMed
      93. Akhavan D, Cloughesy TF, Mischel P. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010 Aug; 12(8):882-9. PMID: 20472883.
        View in: PubMed
      94. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel P, Lo RS, Ribas A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010; 8:39. PMID: 20406486.
        View in: PubMed
      95. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel P, Perera T, Mellinghoff IK. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 6; 107(14):6459-64. PMID: 20308550.
        View in: PubMed
      96. Guo D, Cloughesy TF, Radu CG, Mischel P. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle. 2010 Jan 15; 9(2):211-2. PMID: 20023392.
        View in: PubMed
      97. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel P. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009; 2(101):ra82. PMID: 20009104.
        View in: PubMed
      98. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel P, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010 Jan; 42(1):77-82. PMID: 19946270.
        View in: PubMed
      99. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathol. 2010 Jul; 20(4):751-62. PMID: 20015288.
        View in: PubMed
      100. Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel P, Ng T, Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol. 2009 Nov 17; 19(21):1788-98. PMID: 19836242.
        View in: PubMed
      101. Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel P, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19479-84. PMID: 19846776.
        View in: PubMed
      102. Mischel P. A case for a science-informed perspective on health care reform. J Clin Invest. 2009 Oct; 119(10):2855. PMID: 20069712.
        View in: PubMed
      103. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel P. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 1; 69(17):6889-98. PMID: 19690143.
        View in: PubMed
      104. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel P, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol. 2010 Feb; 96(3):359-67. PMID: 19655089.
        View in: PubMed
      105. Iwanami A, Cloughesy TF, Mischel P. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes Dev. 2009 Aug 1; 23(15):1699-704. PMID: 19651981.
        View in: PubMed
      106. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel P. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 4; 106(31):12932-7. PMID: 19625624.
        View in: PubMed
      107. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel P, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009 Jul 7; 16(1):44-54. PMID: 19573811.
        View in: PubMed
      108. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel P, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul; 252(1):182-9. PMID: 19561256.
        View in: PubMed
      109. Huang TT, Sarkaria SM, Cloughesy TF, Mischel P. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics. 2009 Jul; 6(3):500-12. PMID: 19560740.
        View in: PubMed
      110. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel P, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A. 2009 Jun 9; 106(23):9435-40. PMID: 19478061.
        View in: PubMed
      111. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel P, Lane TF, Liau LM, Nelson SF, Tso CL. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol. 2009 Aug; 94(1):1-19. PMID: 19468690.
        View in: PubMed
      112. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel P, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009 Apr 7; 72(14):1217-22. PMID: 19349600.
        View in: PubMed
      113. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel P, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009 Apr; 27(4):980-7. PMID: 19353526.
        View in: PubMed
      114. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel P, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009 Apr 1; 69(7):3173-9. PMID: 19318569.
        View in: PubMed
      115. Kreisl TN, Lassman AB, Mischel P, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar; 92(1):99-105. PMID: 19018475.
        View in: PubMed
      116. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008 Dec 1; 26(34):5603-9. PMID: 18955445.
        View in: PubMed
      117. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel P, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008; 1:52. PMID: 18940004.
        View in: PubMed
      118. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel P, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008 Oct; 249(1):268-77. PMID: 18796682.
        View in: PubMed
      119. de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel P, Louis DN, Bonni A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci. 2008 Jun 4; 28(23):5870-8. PMID: 18524891.
        View in: PubMed
      120. Inge LJ, Rajasekaran SA, Yoshimoto K, Mischel P, McBride W, Landaw E, Rajasekaran AK. Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit. Histol Histopathol. 2008 Apr; 23(4):459-67. PMID: 18228203.
        View in: PubMed
      121. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008 Aug 1; 71(5):1372-80. PMID: 18355978.
        View in: PubMed
      122. Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, Dang J, Mischel P, Baldwin WM, Fishbein MC, Kupiec-Weglinski JW, Reed EF. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008 Feb 15; 180(4):2214-24. PMID: 18250428.
        View in: PubMed
      123. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel P, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22; 5(1):e8. PMID: 18215105.
        View in: PubMed
      124. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel P. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15; 14(2):488-93. PMID: 18223223.
        View in: PubMed
      125. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel P, Terskikh AV, Kornblum HI. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008 Jan; 86(1):48-60. PMID: 17722061.
        View in: PubMed
      126. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel P, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12. PMID: 18077431.
        View in: PubMed
      127. Weaver JD, Vinters HV, Koretz B, Xiong Z, Mischel P, Kado D. Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist. 2007 May; 13(3):150-3. PMID: 17495760.
        View in: PubMed
      128. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel P, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007 May 1; 13(9):2592-8. PMID: 17473188.
        View in: PubMed
      129. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel P, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. PMID: 17293865.
        View in: PubMed
      130. Mellinghoff IK, Cloughesy TF, Mischel P. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):378-81. PMID: 17255257.
        View in: PubMed
      131. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel P, Stokoe D, Pieper RO. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007 Jan; 13(1):84-8. PMID: 17159987.
        View in: PubMed
      132. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485. PMID: 17177598.
        View in: PubMed
      133. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel P. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17402-7. PMID: 17090670.
        View in: PubMed
      134. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel P, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006 Sep; 4(9):607-19. PMID: 16966431.
        View in: PubMed
      135. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel P. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. PMID: 16912159.
        View in: PubMed
      136. Wang CC, Liao YP, Mischel P, Iwamoto KS, Cacalano NA, McBride WH. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res. 2006 Jul 1; 66(13):6756-62. PMID: 16818651.
        View in: PubMed
      137. Mischel P, Cloughesy T. Using molecular information to guide brain tumor therapy. Nat Clin Pract Neurol. 2006 May; 2(5):232-3. PMID: 16932555.
        View in: PubMed
      138. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006 Apr 25; 66(8):1258-60. PMID: 16636248.
        View in: PubMed
      139. Carlson MR, Zhang B, Fang Z, Mischel P, Horvath S, Nelson SF. Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics. 2006; 7:40. PMID: 16515682.
        View in: PubMed
      140. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel P, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006 Jan 1; 66(1):159-67. PMID: 16397228.
        View in: PubMed
      141. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel P. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. PMID: 16282176.
        View in: PubMed
      142. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel P, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005 Nov-Dec; 26(10):2466-74. PMID: 16286386.
        View in: PubMed
      143. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel P, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1; 11(15):5515-25. PMID: 16061868.
        View in: PubMed
      144. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun; 46(6):945-52. PMID: 15937304.
        View in: PubMed
      145. Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel P, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res Mol Brain Res. 2005 May 20; 136(1-2):99-103. PMID: 15893592.
        View in: PubMed
      146. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel P. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 2005 Jul 22; 280(29):26953-64. PMID: 15908427.
        View in: PubMed
      147. Stillman BN, Mischel P, Baum LG. New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. Brain Pathol. 2005 Apr; 15(2):124-32. PMID: 15912884.
        View in: PubMed
      148. Mischel P, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004 Oct; 5(10):782-92. PMID: 15378038.
        View in: PubMed
      149. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel P, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004 Sep 15; 64(18):6503-10. PMID: 15374961.
        View in: PubMed
      150. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel P. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 2004 Feb 12; 23(6):1283-90. PMID: 14961077.
        View in: PubMed
      151. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel P. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 2004 Jan; 84(1):8-20. PMID: 14631378.
        View in: PubMed
      152. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel P, Nelson SF. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003 Jul 31; 22(31):4918-23. PMID: 12894235.
        View in: PubMed
      153. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel P. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003 Jun 1; 63(11):2742-6. PMID: 12782577.
        View in: PubMed
      154. Mischel P, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2003 May-Jun; 2(3):242-7. PMID: 12878856.
        View in: PubMed
      155. Mischel P, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003 Apr 17; 22(15):2361-73. PMID: 12700671.
        View in: PubMed
      156. Mischel P, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol. 2003 Jan; 13(1):52-61. PMID: 12580545.
        View in: PubMed
      157. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel P. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002 Sep; 8(9):2894-901. PMID: 12231534.
        View in: PubMed
      158. Mischel P, Umbach JA, Eskandari S, Smith SG, Gundersen CB, Zampighi GA. Nerve growth factor signals via preexisting TrkA receptor oligomers. Biophys J. 2002 Aug; 83(2):968-76. PMID: 12124278.
        View in: PubMed
      159. Catania MG, Mischel P, Vinters HV. Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J Neuropathol Exp Neurol. 2001 Jul; 60(7):711-23. PMID: 11444800.
        View in: PubMed
      160. Mischel P, Smith SG, Vining ER, Valletta JS, Mobley WC, Reichardt LF. The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through TrkA. J Biol Chem. 2001 Apr 6; 276(14):11294-301. PMID: 11150291.
        View in: PubMed
      161. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel P, Belldegrun A, Cloughesy TF. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000; 9(6):e8. PMID: 16817691.
        View in: PubMed
      162. Vinters HV, Park SH, Johnson MW, Mischel P, Catania M, Kerfoot C. Cortical dysplasia, genetic abnormalities and neurocutaneous syndromes. Dev Neurosci. 1999 Nov; 21(3-5):248-59. PMID: 10575248.
        View in: PubMed
      163. Bakshi R, Mazziotta JC, Mischel P, Jahan R, Seligson DB, Vinters HV. Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings. Dement Geriatr Cogn Disord. 1999 Mar-Apr; 10(2):152-7. PMID: 10026390.
        View in: PubMed
      164. Jahan R, Mischel P, Curran JG, Peacock WJ, Shields DW, Vinters HV. Bilateral neuropathologic changes in a child with hemimegalencephaly. Pediatr Neurol. 1997 Nov; 17(4):344-9. PMID: 9436800.
        View in: PubMed
      165. Menchine M, Emelin JK, Mischel P, Haag TA, Norman MG, Pepkowitz SH, Welsh CT, Townsend JJ, Vinters HV. Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. Mod Pathol. 1996 Nov; 9(11):1071-80. PMID: 8933518.
        View in: PubMed
      166. De Salles AA, Solberg TD, Mischel P, Massoud TF, Plasencia A, Goetsch S, De Souza E, Viñuela F. Arteriovenous malformation animal model for radiosurgery: the rete mirabile. AJNR Am J Neuroradiol. 1996 Sep; 17(8):1451-8. PMID: 8883640.
        View in: PubMed
      167. Mathern GW, Babb TL, Mischel P, Vinters HV, Pretorius JK, Leite JP, Peacock WJ. Childhood generalized and mesial temporal epilepsies demonstrate different amounts and patterns of hippocampal neuron loss and mossy fibre synaptic reorganization. Brain. 1996 Jun; 119 ( Pt 3):965-87. PMID: 8673505.
        View in: PubMed
      168. Vinters HV, Mischel P, Ranchod M. Central nervous system. Pathology (Phila). 1996; 3(2):513-34. PMID: 8795833.
        View in: PubMed
      169. Farahani K, Mischel P, Black KL, De Salles AA, Anzai Y, Lufkin RB. Hyperacute thermal lesions: MR imaging evaluation of development in the brain. Radiology. 1995 Aug; 196(2):517-20. PMID: 7617870.
        View in: PubMed
      170. Mischel P, Vinters HV. Neuropathology. Neurosurg Clin N Am. 1995 Jul; 6(3):565-79. PMID: 7670329.
        View in: PubMed
      171. Geschwind DH, FitzPatrick M, Mischel P, Cummings JL. Sneddon's syndrome is a thrombotic vasculopathy: neuropathologic and neuroradiologic evidence. Neurology. 1995 Mar; 45(3 Pt 1):557-60. PMID: 7898716.
        View in: PubMed
      172. Mischel P, Nguyen LP, Vinters HV. Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol. 1995 Mar; 54(2):137-53. PMID: 7876884.
        View in: PubMed
      173. Mischel P, Vinters HV. Coccidioidomycosis of the central nervous system: neuropathological and vasculopathic manifestations and clinical correlates. Clin Infect Dis. 1995 Feb; 20(2):400-5. PMID: 7742448.
        View in: PubMed
      174. McPherson SE, Kuratani JD, Cummings JL, Shih J, Mischel P, Vinters HV. Creutzfeldt-Jakob disease with mixed transcortical aphasia: insights into echolalia. Behav Neurol. 1994; 7(3):197-203. PMID: 24487337.
        View in: PubMed
      Paul's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _